Investing.com - Avadel Pharma reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-0.19 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.2557 on revenue of $0.00.
Avadel Pharma shares are up 10% from the beginning of the year and are trading at $7.68 , down-from-52-week-high.They are outperforming the Euro Stoxx 50 which is up 6.48% from the start of the year.
Avadel Pharma shares gained 1.99% in intra-day trade the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by Medtronic on February 23, who reported EPS of $1.29 on revenue of $7.78B, compared to forecasts EPS of $1.15 on revenue of $7.77B.
AstraZeneca ADR had missed expectations on February 11 with fourth quarter EPS of $0.535 on revenue of $7.41B, compared to forecast for EPS of $0.5504 on revenue of $7.12B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar